you, Thank Alexander.
developed X, development and clinical Slide our an flu with me overview start of let on jointly GSK. for So vaccine programs with COVID-XX
we modified technology preferred identified this data reported further vaccines prophylactic a preliminary year, mRNA the in both for indications. the as clinical for earlier development With
study being summarize are the finalized. monovalent second-generation for modified final study studies studies, both mRNA for applying at bottom the the FLU SV the CVXXXX COVID-XX backbone top the the readout On construct, ongoing data currently left, monovalent we for and flu at currently left. The left,
upcoming you the right indications. Alexander the mentioned can On in studies side the both see of slide,
addressing constructs, At the four for escalation all vaccine adults Phase the influencer and flu multivalent Phase assess and and shortly initial study vaccine. be dose and younger the X/X of Belgium. top with to the right, expected licensed constructs initiated versus is part in a a start older reactogenicity U.S. will It safety, also be healthy, will in combined WHO will immunogenicity recommended modified conducted strains. comparator The X
the vaccine mRNA SARS-CoVX construct addressing trial upcoming COVID-XX at the Phase and other a and For will sites versus healthy in in later expected mono study adults the start XXXX, in licensed on clinically bottom Germany, is older and comparator relevant X The right, bivalent countries. with to variants. Belgium modified be a clinical conducted younger study U.S., and
update now immunogenicity like study. preliminary as for XX, walk you would reported were levels comprehensive, On data Omicron to data me preliminary from encoding BA.X COVID-XX Slide CVXXXX the variant. on previously flu as outstanding Phase reactogenicity well the data positive X the already While an dose let for updated we provide for through quite
group adults. or illustrated data tested of XX to years. adult figure the in the adverse data older Both the In within reactogenicity adult booster younger in vaccination younger and the X and doses XX after days previously aged presented greater newly represents on years XX unavailable The the adults, only dose features are the upper X equal left groups micrograms. in X events group the solicited younger to aged
generally dose of events. the data previously adverse to occurred micrograms, no be reactogenicity the and Overall, In both across fatigue. consistent event XXX that tested Here, older figure data solicited in at confirmed and available showed age with is all X are one at adverse X micrograms CVXXXX XXX Grade reported age Grade reported the new newly in which levels. the adults, was solicited lower data groups groups tolerated and levels well dose both X
the to GMI pre-boost titers variant the titers, activity against or neutralizing of the groups responses both are in Antibody The mean table of antibody a increase BA.X the post shown across to right. age boosting in represents to short, geometric for antibody [indiscernible] of data as levels reported mean between geometric when XX ranged and XX adults, of antibody X were depending measured. dose older titers younger at day and the CVXXXX. on X XX micrograms, increases adults between of for and X Previously [indiscernible] the ratio
GMI day on being preliminary Data induces at data new XX at as this currently finalized. for The and confirm tested meaningful antibody X After even dose range are dose. XX study, further is data available. the flu CVXXXX before as lowest day data the final completed update become well micrograms that X X responses now not CVXXXX in in the anticipating Phase COVID-XX the we at updates
expansion attention continued progress once our oncology, Slide me vaccines. next oncology in to let prophylactic area. are I On rapidly growth like strategy your which to driver, would our the to turn this, advancing and in gears for addition our draw again we XX, With now to shift
key all in the acquired have and needed XXXX, to in components oncology. With we achievements assembled succeed
We backbone that immune to second-generation potent raise a responses tolerable ability have has in highly flu shown COVID. and and mRNA clinically strong its
and for discovery antigens. platform and the bioinformatics of We new a cutting-edge integrated tumor have differentiated genomics
avenues R&D cancer printer, systems manufacturing oncology such providing We vaccines. by cell rapid critical open enables scalable complemented improved cancer in applications. flexible T our responses commercial vaccines or are the mRNA-based in is personalized dedicated RNA availability scale most expected finally, and LNP and to of nanoparticle, are new enhancing which And from lipid as enabling which the oncology to are rapidly technologies, immune specifically short progressing that for
provide end, a off in in and with already as broader elements be leverage and together cancer for well oncology. this will these study track shelf our of Alexander anticipated be in together, need be vaccine successful initiated kick resected the up has the noted, on XX quarter to portfolio second therapies. to Taken To XXXX, key a bring XXXX. of as we glioblastoma to candidates deliverable novel In them well off fully personalized proof-of-principle patients surgically as is the to
The study in of be for assess in immunogenicity from Phase Belgium over-expressed tumor-associated dose in the the second The backbone epitopes Netherlands, and second-generation data Germany, the of is escalation construct, derived the will X safety and X mRNA our XXXX. will antigens conducted encoding and half expected first glioblastoma. readout trial
to multi-epitope material and construct, trial successful the achieved already With the study. setup clinical study initiate manufacture of we have of the milestones important complex
compartment, mice, distribution a temperature previously and of well immune a as room as good showed new system that of responses efficacy We to dried itself, in the important the of enabler PEG-free a developments an research oncology. mRNA our is Now composition stability well lipid presentation. consisting as for reported potency vaccine LNP vaccines as is an Therefore, combination well the LNP a highly as the construct localized mRNA the in system of our LNP prophylactic good the as that in cells. the transports proprietary cellular mRNA tumoral as
Taking specific prophylactic delivery we effective well that now LNP efficient mRNA vaccines requirements cancer for developing for to as this address both systems the as vaccines. are level, next research
Slide LNP on implied systems systems. for different, vaccines the need requirements development vaccines the prophylactic of the XX, and for are cancer application-specific for illustrating LNP As
By of prophylactic tumoral primarily namely antibodies. responses, were induced induction vaccines, strong vaccines
we as individuals. signaling Prophylactic minimize the activate of for tumor-killing the For induction responses seriously vaccines, in cells critical. need reactogenicity to are immune strong need in systemic patients. to vaccines vaccines Cancer induction healthy mostly cell T is ill of cancer treating pathways
vaccines to those need cytokines signaling represent T as standard, enough certain or and induction can of they for but term essential then temperature. longer stable of at a a response. lastly, the to really lead higher for storage prophylactic And room be reactogenicity, in cell seasonal is pathways Activation even chemokines refrigerator
us distinct stronger vaccines, clinical finding efficacy. stability can most LNP concentration, in is their be the and cancer For specific to to deprioritized lipids, choice allows that settings. research of tailor favor in responses important composition The immune our of
on can Full data presented cells. components immune systems you a this comparison of concentrations as Biology IL The lipid ability workshop figure to such Organization studies vitro their illustrates XX, was and systems interferon excerpt human data with X comprehensive in Slide IFN see left and the of European selected the Molecular April year. LNP induce at from inflammatory the different varying in On LNP [ph]. cytokines, in
T in the of induction system The of a a induction cancer the of important cell response inflammatory cytokines indicator is critical absolutely an the by in strong relevant immune cancer with are setting. first is and innate for a characteristics response. signals prophylactic left the Accordingly, cytokine but vaccine LNP the X favorable developing less a and vaccine, detected #X for are on
right induction to response you the again, of between see can antigen as amount as to immune relevant CDXX a cells cells the the slide, be cells. of published cell cells of immune correlation for is, appears marker. side abundance an of CDX-positive activation Activation the corresponding the T presenting of antigen-presenting antigen-presenting according T the via literature, On and activated there activation of quantified a
So the LNP vaccine. cancer activation corresponding cells strong X, represent again, pathways design needed induction of and in of and cytokine a antigen-presenting for essential the #X of characteristics signaling
pipeline. a comprehensive the further of Our efficacy, specific applications. critical further We differentiate tailored safety mice generated studies immune vivo consider design enable and systems to our endure mRNA here, for that platform which complementary demonstrate in responses our to design development the us also stability shown technology and potential our to tailored data LNP specific LNP with not improve ability in our
call back me Alexander. to let the this, With hand
